RT Journal Article
SR Electronic
T1 Antibody binding to native cytomegalovirus glycoprotein B predicts vaccine efficacy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.27.20028563
DO 10.1101/2020.02.27.20028563
A1 Jennifer A. Jenks
A1 Cody S. Nelson
A1 Hunter K. Roark
A1 Matt Goodwin
A1 Robert F. Pass
A1 David I. Bernstein
A1 Emmanuel B. Walter
A1 Kathryn M. Edwards
A1 Dai Wang
A1 Tong-Ming Fu
A1 Zhiqiang An
A1 Cliburn Chan
A1 Sallie R. Permar
YR 2020
UL http://medrxiv.org/content/early/2020/03/01/2020.02.27.20028563.abstract
AB Human cytomegalovirus (HCMV) is the most common infectious cause of congenital disease and post-transplant complications worldwide, yet vaccine development remains hampered by a limited understanding of protective immune responses. We investigated humoral immune correlates of protection against HCMV acquisition elicited by the most efficacious HCMV vaccine tested to-date, soluble glycoprotein B (gB) with MF59 adjuvant (gB/MF59), which achieved ∼50% efficacy in two phase II clinical trials. Protection against primary infection correlated with high magnitude antibody binding to gB expressed on a cell surface, but not to the vaccine antigen. Further, we identified monoclonal antibodies that differentially recognized soluble and cell-associated gB, highlighting structural differences essential for protective immunity. These results indicate the importance of the native, cell-associated gB conformation in future HCMV vaccine design.One Sentence Summary Partially-effective HCMV gB/MF59 vaccine-elicited IgG binding to cell-associated gB correlates with protection against HCMVCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by: NIH/NIAID R21 to S.R.P. (R21AI136556), NIH/NIAID P01 to S.R.P. (1P01AI129859), and NIH/NICHD F30 grant to C.S.N. (F30HD089577). The funders had no role in study design, data collection and interpretation, decision to publish, or the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe complete immunogenicity datasets and reproducible Jupyter notebooks for all analysis performed will be later provided in the Supplementary Materials.